Page 47 - 《中国药房》2025年18期
P. 47

成、侵袭能力均显著回升,且接近对照组水平。这提示                                migration  via  PI3K/Akt  pathway[J].  Oncotarget,2018,9
          PI3K/Akt 信号通路可能是 EGCG 增强仑伐替尼抗肝癌                        (15):12261-12272.
          活性的关键调控靶点。                                         [13]  MEHMOOD S,MAQSOOD M,MAHTAB N,et al. Epi‐
              综上所述,EGCG可增加肝癌细胞对仑伐替尼的敏                             gallocatechin gallate:phytochemistry,bioavailability,utili‐
          感性,其作用机制可能与抑制PI3K/Akt信号通路激活有                            zation  challenges,and  strategies[J].  J  Food  Biochem,
                                                                  2022,46(8):e14189.
          关。本研究为增强仑伐替尼治疗敏感性提供了实验参
                                                             [14]  GU J J,QIAO K S,SUN P,et al. Study of EGCG induced
          考,对挖掘新的治疗策略、提高肝癌患者的治疗效果具
                                                                  apoptosis in lung cancer cells by inhibiting PI3K/Akt sig‐
          有重要意义。
                                                                  naling pathway[J]. Eur Rev Med Pharmacol Sci,2018,22
          参考文献                                                   (14):4557-4563.
          [ 1 ]  赵海潮,高强 . 2022 年度肝癌研究及诊疗新进展[J]. 中            [15]  WEI Y C,YANG L,TANG C W,et al. Lenvatinib inhibits
              国癌症杂志,2023,33(4):315-326.                           cholangiocarcinoma  progression  by  targeting  the  FGF19/
          [ 2 ]  张劲丰,安宏亮,苏荣,等. 乙型肝炎病毒耐药性研究进                       PI3K/Akt  signaling  pathway[J].  Apoptosis,2025,30(1/
              展[J]. 分子诊断与治疗杂志,2019,11(5):434-440.                 2):185-196.
          [ 3 ]  熊洪莉,陈君辉,王雪. 心理护理对介入治疗围手术期肝                  [16]  LIU S M,SUN Z W,CHU P,et al. EGCG protects against
              癌患者焦虑抑郁水平影响的临床对照研究[J]. 四川精神                         homocysteine-induced  human  umbilical  vein  endothelial
              卫生,2015,28(3):227-229.                              cells  apoptosis  by  modulating  mitochondrial-dependent
          [ 4 ]  NAING  C,NI  H,AUNG  H  H,et  al.  Gene  therapy  for   apoptotic  signaling  and  PI3K/Akt/ENOS  signaling  path‐
              people  with  hepatocellular  carcinoma[J].  Cochrane  Data‐  ways[J]. Apoptosis,2017,22(5):672-680.
              base Syst Rev,2024,6(6):CD013731.              [17]  DING F,YANG S. Epigallocatechin-3-gallate inhibits pro‐
          [ 5 ]  杨欣荣,孙惠川,谢青,等. 仑伐替尼肝癌全病程应用中                       liferation  and  triggers  apoptosis  in  colon  cancer  via  the
              国专家指导意见[J]. 中华消化外科杂志,2023,22(2):                    hedgehog/phosphoinositide  3-kinase  pathways[J].  Can  J
              167-180.                                            Physiol Pharmacol,2021,99(9):910-920.
          [ 6 ]  WANG L,LIN L,ZHOU W. Efficacy and safety of trans-  [18]  李明龙. EGCG逆转索拉菲(非)尼耐药肝癌细胞的相关
              arterial  chemoembolization  combined  with  lenvatinib  and   机制研究[D]. 延吉:延边大学,2016.
              PD-1 inhibitor in the treatment of advanced hepatocellular   [19]  ZHAI J,HAO H,XU Z,et al. The effect of modulation
              carcinoma:a  meta-analysis[J].  Pharmacol  Ther,2024,  Piezo2  by  IGF-1  on  tactile  hypersensitivity  in  BTBR
              257:108634.                                         model mice[J]. Life Sci,2025,364:123449.
          [ 7 ]  CHAN L L,CHAN S L. The evolving role of lenvatinib at   [20]  中华人民共和国国家卫生健康委员会医政司. 原发性肝
              the  new  era  of  first-line  hepatocellular  carcinoma  treat‐  癌诊疗指南:2024 年版[J]. 中华肝脏病杂志,2024,32
              ment[J]. Clin Mol Hepatol,2023,29(4):909-923.      (7):581-630.
          [ 8 ]  LU Y G,SHEN H M,HUANG W J,et al. Genome-scale   [21]  YANO S,KAWAOKA T,JOHIRA Y,et al. Advanced he‐
              CRISPR-Cas9 knockout screening in hepatocellular carci‐  patocellular  carcinoma  with  response  to  lenvatinib  after
              noma  with  lenvatinib  resistance[J].  Cell  Death  Discov,  atezolizumab plus bevacizumab[J]. Medicine(Baltimore),
              2021,7(1):359.                                      2021,100(42):e27576.
          [ 9 ]  TALIB W H,AWAJAN D,ALQUDAH A,et al. Targeting   [22]  BUTTELL A,QIU W. The action and  resistance mecha‐
              cancer  hallmarks  with  epigallocatechin  gallate(EGCG):  nisms  of  lenvatinib  in  liver  cancer[J].  Mol  Carcinog,
              mechanistic  basis  and  therapeutic  targets[J].  Molecules,  2023,62(12):1918-1934.
              2024,29(6):1373.                               [23]  GUAN Y T,WU Q L,LI M M,et al. Epigallocatechin-
          [10]  ALMATROODI S A,ALMATROUDI A,KHAN A A,et           3-gallate  induced  HepG2  cells  apoptosis  through  ROS
              al. Potential therapeutic targets of epigallocatechin gallate  mediated  Akt/JNK  and  p53  signaling  pathway[J].  Curr
              (EGCG),the most abundant catechin in green tea,and its   Cancer Drug Targets,2023,23(6):447-460.
              role  in  the  therapy  of  various  types  of  cancer[J].  Mole-  [24]  MORADZADEH M,HOSSEINI A,ERFANIAN S,et al.
              cules,2020,25(14):3146.                             Epigallocatechin-3-gallate  promotes  apoptosis  in  human
          [11]  DU B X,LIN P,LIN J. EGCG and ECG induce apoptosis   breast  cancer  T47D  cells  through  down-regulation  of
              and decrease autophagy via the AMPK/mTOR and PI3K/  PI3K/Akt  and  telomerase[J].  Pharmacol  Rep,2017,69
              Akt/mTOR pathway in human melanoma cells[J]. Chin J   (5):924-928.
              Nat Med,2022,20(4):290-300.                                   (收稿日期:2025-03-26  修回日期:2025-07-29)
          [12]  LUO K W,LUNG W Y,CHUN-XIE,et al. EGCG inhi-                                       (编辑:张元媛)
              bited bladder cancer T24 and 5637 cell proliferation and




          中国药房  2025年第36卷第18期                                              China Pharmacy  2025 Vol. 36  No. 18    · 2261 ·
   42   43   44   45   46   47   48   49   50   51   52